Clinical Trial

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Study acronym: NOVA-1
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-10 -> 2027-05 2026-05-27
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-20
Trial Details
NCT Number NCT05769153
Lead Sponsor Alcon Research
Conditions Neovascular Age-related Macular Degeneration (nAMD)
Enrollment 139 participants
Start Date 2023-12-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-26